header
Image from OpenLibrary

Osteosarcoma of the extremities at National Cancer Institute (Cairo University Egypt), treatment outcome and prognostic factors / Amira Youssef Hussein ; Supervised Emad N. Ebeid , Magdy Elsherbiny , Reham Abdelaziz

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Amira Youssef Hussein , 2017Description: 166 P. : charts ; 25cmOther title:
  • العوامل المؤثرة على تطور المرض فى حالاث القرن العظمى المعهد القىمى للأورام {u٢٠١٣} القاهرة جامعة القاهرة [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology Summary: Osteosarcoma accounting for less than %2.0 of malignant tumors and about 65 % of all bone cancers in individuals under the age of .%, although the overall survival have improved dramatically yet it remains a challenging disease especially in developing countries. Thirty one (13) of newly diagnosed osteosarcoma patients who presented to National Cancer Institute, Cairo University, Egypt were considered eligible in this retrospective study, aiming for identifying survival outcome and correlation of outcome with different risk factors. Available data of the included patients were collected such as; age, gender, primary tumor volume, and extent of the disease. The 1 years DFS was found to be 1.53 %. The 1 years OS was 3357%.Tumor volume, elevated alkaline phosphatase at presentation, positive surgical margin and delay of resuming chemotherapy more than 12 days post-surgery proved to be statistically significant and had their impact on survival. Other factors proved to be insignificant. Although HDMTX and cisplatin free regimen produce outcome comparable to other protocols using cisplatin and HDMTX-containing regimens and offers a good alternative for patients particularly those with intolerance to HDMTX and for institutions that cannot provide HDMTX pharmacokinetic monitoring in other countries, our study protocol does not seem reasonable for our patient population due to its poor outcome when compared to other studies
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.05.M.Sc.2017.Am.O (Browse shelf(Opens below)) Not for loan 01010110075516000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.19.05.M.Sc.2017.Am.O (Browse shelf(Opens below)) 75516.CD Not for loan 01020110075516000

Thesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Pediatric Oncology

Osteosarcoma accounting for less than %2.0 of malignant tumors and about 65 % of all bone cancers in individuals under the age of .%, although the overall survival have improved dramatically yet it remains a challenging disease especially in developing countries. Thirty one (13) of newly diagnosed osteosarcoma patients who presented to National Cancer Institute, Cairo University, Egypt were considered eligible in this retrospective study, aiming for identifying survival outcome and correlation of outcome with different risk factors. Available data of the included patients were collected such as; age, gender, primary tumor volume, and extent of the disease. The 1 years DFS was found to be 1.53 %. The 1 years OS was 3357%.Tumor volume, elevated alkaline phosphatase at presentation, positive surgical margin and delay of resuming chemotherapy more than 12 days post-surgery proved to be statistically significant and had their impact on survival. Other factors proved to be insignificant. Although HDMTX and cisplatin free regimen produce outcome comparable to other protocols using cisplatin and HDMTX-containing regimens and offers a good alternative for patients particularly those with intolerance to HDMTX and for institutions that cannot provide HDMTX pharmacokinetic monitoring in other countries, our study protocol does not seem reasonable for our patient population due to its poor outcome when compared to other studies

Issued also as CD

There are no comments on this title.

to post a comment.